There’s going big.
And then there’s engineering at genome scale.


The Write” revolution

This is an exciting time for biology – after centuries of empirical approaches, we can now actively participate in engineering biological systems. We are taking inspiration from the molecular mechanisms that evolved in nature over billions of years and using those to guide our methods in the lab. By removing the technical barriers, we let scientific questions drive the research.

Technology used in the Onyx® platform

The CRISPR revolution

CRISPR gene editing might be the single most important biological discovery of this century. It took many brilliant minds and years of experimentation to coalesce into a discovery that transformed the way we approach biology. With this powerful tool in hand, scientists today are making tomorrow’s history.

CRISPR editing provides a clever method to introduce precise DNA changes at specified genomic locations, allowing researchers to modify virtually any coding or non-coding region of the genome. Learn more about the history of CRISPR technology development and how CRISPR editing works.

Why digital?

Until now, CRISPR-based genome editing has been limited in throughput, barely scratching the surface of its full potential. Our Digital Genome Engineering technology automates the design, engineering, and tracking steps, allowing you to test thousands of biological hypotheses in parallel. 

For the first time ever, you’ll be able to make various types of edits across the entire genome at a highly multiplexed scale – all from your own lab bench. Seamless trackability of individual edits in cells lets you know what was successfully incorporated, while high edit rates ensure experimental efficiency.


The MAD7™ nuclease: made for discovery

We believe genome engineering will power the bioeconomy and help scientists solve some of today’s most pressing challenges. This is why we have developed our own CRISPR nuclease — to make genome editing more accessible and empower researchers to own their discoveries. Click below to learn more about MAD7 nuclease and our decision to make it free for non-commercial use.

Safety. Always first.

Our goal is to ensure everyone’s safety while also minimizing impact on customer workflows.

Keeping you at the cutting edge of genome engineering is our specialty. However, ensuring that genome engineering is safely executed every step of the way is our primary responsibility. Inscripta’s proactive biosecurity screening process aims to identify and prevent both deliberate and accidental biorisk. Our industry-standard biosecurity screening processes endeavor to detect and block anyone that is on government banned lists.

In addition, we carry out extensive in silico screening on all genomes and design libraries, identifying potential biorisks before sequences are released for reagent production. In the event of a biosecurity alert, we collaborate with customers to avoid or remove the potential biorisk scenarios.